Under the terms of the agreement, Biogen will make an upfront payment of US $ 8 million to Xbrane
The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
This test analyses samples in VTM directly without the need for RNA extraction step
Biogen paid Ionis a US $ 60 million one-time upfront payment
Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
It becomes the first ophthalmology biosimilar to gain FDA approval in the United States
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
Subscribe To Our Newsletter & Stay Updated
